CD8A and neoplasm: While Lm vaccines have demonstrated poor CD8+ T-cell priming for some tumor antigens10,11, we hypothesized that its resistance to vector-specific immunity may make it an ideal platform for prime-boost strategies following Ad5.F35-based vaccines.